Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

hich may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2009, and statements regarding our clinical development programs, the effectiveness of our Vancocin and Cinryze sales efforts, our estimates of future tax rates, or our ability to execute a successful launch of Cinryze, our ability to conduct future studies with maribavir, and the timing and potential outcomes of the review of our regulatory submission related to an acute treatment indication for Cinryze.

Our 2009 revenue guidance is based upon our plans to remain vigorous in our opposition to any bioequivalence approach considered for use in approving generic formulations of Vancocin that does not require rigorous scientific methods to demonstrate safety and efficacy consistent with good medicine and science. There can be no assurance that the FDA will agree with the positions stated in our Vancocin related submissions or that our efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the FDA in December 2008, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancoci
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Seoul Semiconductor (CEO: Chung-hoon ... technology, on May 28th announced that it will ... strengthening its high efficient and high reliable LED ... 2011 Seoul Semiconductor has developed efficient and reliable ... has supplied LEDs for headlamps to global auto ...
(Date:5/28/2015)... 28, 2015 ... announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... describes and evaluates animal biotechnology and ... pharmaceuticals as well as improvement in ...
(Date:5/28/2015)... IN (PRWEB) May 28, 2015 The Academy ... National Model Aviation Day on August 15, 2015. National Model ... aviation nation-wide and to introduce model flying to the general ... 2,350 chartered clubs to participate in the celebration by hosting ... registered to host National Model Aviation Day events. View ...
(Date:5/28/2015)... , May 28, 2015  PDS Biotechnology ... cancer immunotherapy treatment targeting HPV-16, has generated strong ... Currently, pre-cervical cancer is treated by surgical ... simple and effective non-surgical alternative. Results show that ... (T-cells) to recognize, target, and kill precancerous and ...
Breaking Biology Technology:Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2
... BOTHELL, WA and VANCOUVER, July 20 /PRNewswire-FirstCall/ - OncoGenex ... it has entered into purchase agreements with certain institutional ... common stock at a price of $20 per share ... to provide gross proceeds of $9.5 million to OncoGenex ...
... , , ST. LOUIS, July 20 ... first outpatient single-site laparoscopic gastric banding surgery in the state of Missouri ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20080812/CLTU111LOGO ... For single-site surgery, the major incision is through the belly button only. ...
... , NEWPORT, R.I., July 20 iSource ... today that it will partner with inVentiv Health, the ... to develop an innovative new technology platform that will ... to better manage their health. The platform will be ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock 2OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock 3Surgeon Performs First Single Incision Peri-Umbilical Laparoscopic Surgery in the State of Missouri 2iSource Networks Partners with inVentiv Health to Develop New Technology Platform for Reaching Healthcare Consumers 2iSource Networks Partners with inVentiv Health to Develop New Technology Platform for Reaching Healthcare Consumers 3
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... of scientists has released data indicating that greenhouse gas ... of methane emissions from freshwater areas. John Downing, ... and organismal biology department, is part of an international ... is higher than previous estimates. The study, ...
... a significant step forward in understanding the atmosphere,s ... some other gases, except carbon dioxide. The issue ... studies suggesting the self-cleaning power of the atmosphere ... others suggest greater stability. And what researchers are ...
... 6, 2011 Acceleron Pharma, Inc., a biopharmaceutical company ... and tissues including muscle, bone, fat, red blood cells ... a $1.5 million grant from the Muscular Dystrophy Association ... Dystrophy (DMD), a disabling neuromuscular disease in which patients ...
Cached Biology News:Freshwater methane release changes greenhouse gas equation 2NOAA-led team measures atmosphere's self-cleaning capacity 2NOAA-led team measures atmosphere's self-cleaning capacity 3Acceleron awarded $1.5 million grant from Muscular Dystrophy Association to support ACE-031 2